Home
Proteomic Services
Cellular & Tissue ProteomicsPlasmaProteomics (BioTAS)Quantitative Assay Translation
BioTAS™
Applications
Drug DevelopmentDiagnostic Assay DevelopmentClinical Trial Support
ResourcesAbout
Start A Project
Proteas Health is a proteomics contract research organization advancing precision medicine through preserved liquid biopsy samples and high-confidence protein analysis.
Xxxxxxxx XX
+1 626 345 8596
Harbor-UCLA Medical Center1124 W. Carson Street Torrance, CA 90502
Quick Links
HomeAbout UsBioTAS™Resources
Proteomic Services
Cellular & Tissue ProteomicsPlasmaProteomics (BioTAS)Quantitative Assay Translation
Applications
Drug DevelopmentDiagnostic Assay DevelopmentClinical Trial Support
Follow Us
Facebook
Instagram
X
LinkedIn
Pinterest
Youtube
© 2026 Proteas Health. All Rights Reserved.
Terms of ConditionsPrivacy PolicyCookie Settings

Proteomic Infrastructure for Drug Development and Diagnostic Programs

Integrated quantitative proteomic workflows across cells, tissue, and plasma – anchored by the globally patented BioTAS™ platform for blood-based analysis and regulated clinical integration.

Start A ProjectExplore BioTAS™

Proteomic Capabilities Aligned to Development Programs

Proteas Health integrates quantitative proteomic workflows into therapeutic and diagnostic development to enable target engagement assessment, systemic drug response evaluation, and structured translational advancement toward clinical-scale assay deployment.

Systems-Level Proteome Characterization

High-resolution quantitative proteome and phosphoproteome profiling to resolve pathway activity, target engagement, and systemic biological response.

Blood Proteomics for Drug Response and Clinical Assay Development

Quantitative plasma proteomic analysis enabled by the BioTAS™ platform to characterize systemic drug effects, define stratification strategies, and establish protein signatures for assay translation.

Quantitative Assay Development

Multiplexed quantitative protein measurement workflows designed for translational confirmation and integration into clinical development programs, including deployment within CLIA-aligned laboratory environments.

The BioTAS™ Platform

BioTAS™ is a globally patented proteomics infrastructure (PCT/US2021/063407) integrating controlled plasma isolation, high-resolution quantitative mass spectrometry, and AI-enabled modeling to deliver reproducible protein measurement across decentralized and CLIA-aligned laboratory environments.

Platform Architecture

  • Proprietary remote blood collection and plasma stabilization
  • Controlled pre-analytical handling to minimize collection variability
  • Quantitative mass spectrometry workflows for reproducible protein measurement
  • AI-enabled proteomic data modeling and temporal pattern analysis
  • Infrastructure supporting assay transfer and multi-site study integration
Learn More About BIOTAS™

Built for Reproducibility and Clinical Scale

Designed for program integration rather than exploratory analysis, our workflows enable multi-site integration, reproducible protein measurement and compatibility with regulated laboratory environments.

  • Inter-operator and inter-instrument reproducibility
  • Low-volume plasma compatibility
  • Standardized analytical workflows
  • Multi-site program integration
  • CLIA-aligned laboratory compatibility

Supporting Programs Across Development Stages

Drug Development

Proteomic integration from preclinical research through Phase I–III clinical trials, supporting target engagement assessment, systemic pharmacodynamic evaluation, and mechanistic validation.

Diagnostic Programs

Development and analytical validation of quantitative plasma assays supporting scalable implementation within CLIA-aligned laboratory environments.

Academic Research

Mechanistic proteomic collaboration for publication-grade biological investigation.

Bring Proteomic Precision to Your Program

Start A ProjectSchedule A Scientific Consultation